Quantcast

Launch of Additional First- and Second-Line Options Will Substantially Expand the Treatment Landscape for Myelodysplastic Syndromes Through 2023

April 3, 2014

Poor Efficacy and Physicians’ Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group

BURLINGTON, Mass., April 3, 2014 /PRNewswire/ — Decision Resources Group finds that azacitidine (Celgene’s Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to clinical trial data and expert opinion, treatment options for MDS will expand significantly over the next decade with the launches of as many as five novel therapies: Cyclacel’s sapacitabine, Mirati Therapeutics’ mocetinostat, Celgene’s oral azacitidine, Onconova’s oral rigosertib and Acceleron/Celgene’s sotatercept, as well as a label extension for GlaxoSmithKline’s Revolade/Promacta.

http://photos.prnewswire.com/prnvar/20130103/MM36768LOGO

Other key findings from the Niche Markets and Rare Diseases Myelodysplastic Syndromes report:

    --  Increase in the size of MDS population: Driven by an aging population,
        the number of newly diagnosed incident cases of MDS in the six major
        markets under study will increase by more than 20 percent during
        2013-2023 study period.
    --  Revlimid approval in Europe: Interviewed experts report that low
        reimbursement obstacles for Celegene's Revlimid in major European
        markets following its 2013 approval are driving expanded use of this
        agent among lower-risk European MDS patients who have the underlying
        chromosomal deletion 5q abnormality. Ongoing trials evaluating use of
        Revlimid in combination with hypomethylating agents, such as
        azacitidine, in higher-risk patients could further drive its uptake and
        overall growth of the MDS market.
    --  Opportunities for new product development: According to thought leaders,
        an improved molecular understanding of MDS could unearth therapeutic
        targets for subpopulations that have poor outcomes with currently
        available therapies. Interviewed experts believe that great strides are
        being made towards a clinically relevant, molecular understanding of
        MDS.
    --  Optimizing drug development in MDS: Interviewed experts call for drug
        developers to facilitate clinical trial recruitment and participation by
        easing financial and logistic burden on both clinicians and their MDS
        patients, such as coordinating recruitment, transportation and lodging
        while receiving investigational agents.

Comments from Decision Resources Group Analyst Jing Wu, M.S., M.B.A.:

    --  "Short of a pharmacological cure, the key unmet needs in MDS are
        improved overall survival and quality of life, which will be addressed
        to some extent by the market entry of novel therapies. Interviewed
        thought leaders note that higher-risk MDS patients are at great risk of
        progressing to acute myeloid leukemia (AML). Physicians believe that
        this pathological connection may allow developers to evaluate AML
        therapies in MDS as they strive towards molecularly-targeted,
        biomarker-enabled therapies."
    --  "By 2023, we believe injectable and oral formulations will together
        maintain azacitidine's status as the patient share leader in MDS.
        Although physicians and patients will prefer the convenience of new oral
        formulation, the availability of generic injectable azacitidine will
        likely hinder uptake of the oral drug."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort

781-993-2597

ccomfort@dresourcesgroup.com

Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group


Source: PR Newswire



comments powered by Disqus